CEO Mark Tarr Sells $16.7M in Company Stock
EHC sits 22% above its 52-week low of $92.53.
Summary
Encompass Health Corp's CEO, Mark J. Tarr, executed an open market sale of 150,000 shares totaling over $16.7 million, following a Form 144 filing on the same day.
Key Events · Ownership and Investor Activity · EHC
-
CEO Executes Significant Stock Sale
Mark J. Tarr, President and CEO of Encompass Health Corp, sold 150,000 shares of common stock in open market transactions.
-
Transaction Valued at Over $16.7 Million
The total value of the shares disposed of by the CEO amounted to $16,746,688.
-
Follows Prior Intent to Sell Disclosure
This Form 4 reports the execution of the sale previously indicated by a Form 144 filed on February 11, 2026.
Analysis · EHC · Industrial Applications And Services
This Form 4 confirms a substantial open market sale by Encompass Health Corp's President and CEO, Mark J. Tarr. The sale of 150,000 shares, valued at over $16.7 million, represents a notable disposition of personal holdings. This transaction follows a Form 144 filed on February 11, 2026, which indicated an intent to sell these shares. While the company recently reported strong Q4 and full-year 2025 financial results on February 5, 2026, a significant sale by the CEO shortly after positive earnings could be viewed as a cautious signal regarding future prospects or simply a diversification/liquidity event. Investors should consider the context of this executive's selling activity.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.1% of the 1703 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EHC was trading at $113.08 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $11.4B. The 52-week trading range was $92.53 to $127.99. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.